Learn more about whether Arrowhead Pharmaceuticals, Inc. or Veracyte, Inc. is a better investment based on AAII's A+ Investor ...

In a report released today, Luca Issi from RBC Capital maintained a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report), with a ...

Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on X4 Pharmaceuticals (XFOR – Research Report) today and set a price target of ...

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) have received an average rating of “Moderate Buy” from the ten ratings firms that are presently covering the firm ...

R Squared Ltd acquired a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The ...

Genelux named Matthew Pulisic as chief financial officer.

The shares were sold at a price of $21 each, totaling $20,139. Following this transaction, Olukotun holds 35,781 shares ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), a biopharmaceutical company with a market capitalization of $2.68 billion specializing in RNA interference (RNAi) technology, is on the cusp of a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Mercedes-Benz of Arrowhead is excited to announce exclusive lease offers on select 2024 Mercedes-Benz models to kick off the ...

PASADENA, Calif., January 22, 2025--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 10, 2025 ...